These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 9934484

  • 41. Design, synthesis, and X-ray crystallographic analysis of a novel class of HIV-1 protease inhibitors.
    Ganguly AK, Alluri SS, Caroccia D, Biswas D, Wang CH, Kang E, Zhang Y, McPhail AT, Carroll SS, Burlein C, Munshi V, Orth P, Strickland C.
    J Med Chem; 2011 Oct 27; 54(20):7176-83. PubMed ID: 21916489
    [Abstract] [Full Text] [Related]

  • 42. Synthesis and evaluation of A-seco type triterpenoids for anti-HIV-1protease activity.
    Wei Y, Ma CM, Hattori M.
    Eur J Med Chem; 2009 Oct 27; 44(10):4112-20. PubMed ID: 19493591
    [Abstract] [Full Text] [Related]

  • 43. Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies.
    Ghosh AK, Leshchenko-Yashchuk S, Anderson DD, Baldridge A, Noetzel M, Miller HB, Tie Y, Wang YF, Koh Y, Weber IT, Mitsuya H.
    J Med Chem; 2009 Jul 09; 52(13):3902-14. PubMed ID: 19473017
    [Abstract] [Full Text] [Related]

  • 44. Design, asymmetric synthesis, and evaluation of pseudosymmetric sulfoximine inhibitors against HIV-1 protease.
    Lu D, Sham YY, Vince R.
    Bioorg Med Chem; 2010 Mar 01; 18(5):2037-48. PubMed ID: 20138769
    [Abstract] [Full Text] [Related]

  • 45. Three-dimensional quantitative structure-activity relationship study on cyclic urea derivatives as HIV-1 protease inhibitors: application of comparative molecular field analysis.
    Debnath AK.
    J Med Chem; 1999 Jan 28; 42(2):249-59. PubMed ID: 9925730
    [Abstract] [Full Text] [Related]

  • 46. Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands.
    Ghosh AK, Sean Fyvie W, Brindisi M, Steffey M, Agniswamy J, Wang YF, Aoki M, Amano M, Weber IT, Mitsuya H.
    Bioorg Med Chem Lett; 2017 Nov 01; 27(21):4925-4931. PubMed ID: 28958624
    [Abstract] [Full Text] [Related]

  • 47. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
    Ghosh AK, Chapsal BD, Weber IT, Mitsuya H.
    Acc Chem Res; 2008 Jan 01; 41(1):78-86. PubMed ID: 17722874
    [Abstract] [Full Text] [Related]

  • 48. Synthesis of di- and tripeptide analogues containing alpha-ketoamide as a new core structure for inhibition of HIV-1 protease.
    Sheha MM, Mahfouz NM, Hassan HY, Youssef AF, Mimoto T, Kiso Y.
    Eur J Med Chem; 2000 Oct 01; 35(10):887-94. PubMed ID: 11121614
    [Abstract] [Full Text] [Related]

  • 49. The synthesis of symmetrical and unsymmetrical P1/P1' cyclic ureas as HIV protease inhibitors.
    Patel M, Kaltenbach RF, Nugiel DA, McHugh RJ, Jadhav PK, Bacheler LT, Cordova BC, Klabe RM, Erickson-Viitanen S, Garber S, Reid C, Seitz SP.
    Bioorg Med Chem Lett; 1998 May 05; 8(9):1077-82. PubMed ID: 9871711
    [Abstract] [Full Text] [Related]

  • 50. Cycloalkylpyranones and cycloalkyldihydropyrones as HIV protease inhibitors: exploring the impact of ring size on structure-activity relationships.
    Romines KR, Morris JK, Howe WJ, Tomich PK, Horng MM, Chong KT, Hinshaw RR, Anderson DJ, Strohbach JW, Turner SR, Mizsak SA.
    J Med Chem; 1996 Sep 27; 39(20):4125-30. PubMed ID: 8831779
    [Abstract] [Full Text] [Related]

  • 51. Structure-based design of non-peptide HIV protease inhibitors.
    Ghosh AK, Shin D, Swanson L, Krishnan K, Cho H, Hussain KA, Walters DE, Holland L, Buthod J.
    Farmaco; 2001 Sep 27; 56(1-2):29-32. PubMed ID: 11347961
    [Abstract] [Full Text] [Related]

  • 52. Design and synthesis of P1-P3 macrocyclic tertiary-alcohol-comprising HIV-1 protease inhibitors.
    Joshi A, Véron JB, Unge J, Rosenquist Å, Wallberg H, Samuelsson B, Hallberg A, Larhed M.
    J Med Chem; 2013 Nov 27; 56(22):8999-9007. PubMed ID: 24160253
    [Abstract] [Full Text] [Related]

  • 53. Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles.
    Miller JF, Brieger M, Furfine ES, Hazen RJ, Kaldor I, Reynolds D, Sherrill RG, Spaltenstein A.
    Bioorg Med Chem Lett; 2005 Aug 01; 15(15):3496-500. PubMed ID: 15990305
    [Abstract] [Full Text] [Related]

  • 54. Structure-guided design of C2-symmetric HIV-1 protease inhibitors based on a pyrrolidine scaffold.
    Blum A, Böttcher J, Heine A, Klebe G, Diederich WE.
    J Med Chem; 2008 Apr 10; 51(7):2078-87. PubMed ID: 18348517
    [Abstract] [Full Text] [Related]

  • 55. A new structural theme in C2-symmetric HIV-1 protease inhibitors: ortho-substituted P1/P1' side chains.
    Wannberg J, Sabnis YA, Vrang L, Samuelsson B, Karlén A, Hallberg A, Larhed M.
    Bioorg Med Chem; 2006 Aug 01; 14(15):5303-15. PubMed ID: 16621572
    [Abstract] [Full Text] [Related]

  • 56. Cage dimeric 4-aryl-1,4-dihydropyridines as promising lead structures for the development of a novel class of HIV-1 protease inhibitors.
    Hilgeroth A, Billich A.
    Arch Pharm (Weinheim); 1999 Jan 01; 332(1):3-5. PubMed ID: 10073137
    [No Abstract] [Full Text] [Related]

  • 57. Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.
    Rodgers JD, Lam PY, Johnson BL, Wang H, Li R, Ru Y, Ko SS, Seitz SP, Trainor GL, Anderson PS, Klabe RM, Bacheler LT, Cordova B, Garber S, Reid C, Wright MR, Chang CH, Erickson-Viitanen S.
    Chem Biol; 1998 Oct 01; 5(10):597-608. PubMed ID: 9818151
    [Abstract] [Full Text] [Related]

  • 58. Discovery of potent HIV-1 protease inhibitors incorporating sulfoximine functionality.
    Lu D, Vince R.
    Bioorg Med Chem Lett; 2007 Oct 15; 17(20):5614-9. PubMed ID: 17822899
    [Abstract] [Full Text] [Related]

  • 59. Potent piperazine hydroxyethylamine HIV protease inhibitors containing novel P3 ligands.
    Chen X, Kempf DJ, Sham HL, Green BE, Molla A, Korneyeva M, Vasavanonda S, Wideburg NE, Saldivar A, Marsh KC, McDonald E, Norbeck DW.
    Bioorg Med Chem Lett; 1998 Dec 15; 8(24):3531-6. PubMed ID: 9934466
    [Abstract] [Full Text] [Related]

  • 60. [Current status of HIV protease inhibitors].
    Yang QG, He XC, Bai DL.
    Yao Xue Xue Bao; 2005 May 15; 40(5):389-94. PubMed ID: 16220778
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.